Publicaciones en las que colabora con MANUEL LIZASOAÍN HERNÁNDEZ (19)

2023

  1. Nirmatrelvir/ritonavir for the treatment of immunocompromised adult patients with early-stage symptomatic COVID-19: A real-life experience

    Journal of Medical Virology, Vol. 95, Núm. 9

  2. Production of OXA-48 carbapenemase acts as an independent risk factor for poor outcome in Klebsiella pneumoniae infection

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 42, Núm. 12, pp. 1485-1497

2022

  1. A predictive score at admission for respiratory failure among hospitalized patients with confirmed 2019 Coronavirus Disease: a simple tool for a complex problem

    Internal and Emergency Medicine, Vol. 17, Núm. 2, pp. 515-524

  2. Analysis of the factors predicting clinical response to tocilizumab therapy in patients with severe COVID-19

    International Journal of Infectious Diseases, Vol. 117, pp. 56-64

  3. Derivation of a score to predict infection due to multidrug-resistant Pseudomonas aeruginosa: a tool for guiding empirical antibiotic treatment

    Journal of Global Antimicrobial Resistance, Vol. 29, pp. 215-221

  4. Effectiveness of ceftazidime-avibactam for the treatment of infections due to Pseudomonas aeruginosa

    International Journal of Antimicrobial Agents, Vol. 59, Núm. 2

  5. Prognostic factors of OXA-48 carbapenemase-producing Klebsiella pneumoniae infection in a tertiary-care Spanish hospital: A retrospective single-center cohort study

    International Journal of Infectious Diseases, Vol. 119, pp. 59-68

  6. Risk Factors and Outcomes for Multidrug Resistant Pseudomonas aeruginosa Infection in Immunocompromised Patients

    Antibiotics, Vol. 11, Núm. 11

2021

  1. Eradication of staphylococcus aureus post-sternotomy mediastinitis following the implementation of universal preoperative nasal decontamination with mupirocin: An interrupted time-series analysis

    Clinical Infectious Diseases, Vol. 73, Núm. 9, pp. 1685-1692

  2. Tocilizumab for the treatment of adult patients with severe COVID-19 pneumonia: A single-center cohort study

    Journal of Medical Virology, Vol. 93, Núm. 2, pp. 831-842

2020

  1. Clinical course and risk factors for mortality from COVID-19 in patients with haematological malignancies

    European Journal of Haematology, Vol. 105, Núm. 5, pp. 597-607

  2. Clinical predictive model of multidrug resistance in neutropenic cancer patients with bloodstream infection due to Pseudomonas aeruginosa

    Antimicrobial Agents and Chemotherapy, Vol. 64, Núm. 4

  3. Incidence and clinical profiles of COVID-19 pneumonia in pregnant women: A single-centre cohort study from Spain

    EClinicalMedicine, Vol. 23

2018

  1. Fármacos antifúngicos

    Velázquez. Farmacología básica y clínica (Editorial Médica Panamericana), pp. 891-909

2017

  1. Manejo de la infección y la neutropenia febril en el paciente con cáncer sólido

    Enfermedades Infecciosas y Microbiologia Clinica

2016

  1. Management of infection and febrile neutropenia in patients with solid cancer

    Clinical and Translational Oncology, Vol. 18, Núm. 6, pp. 557-570

2004

  1. Fármacos antifúngicos

    Velázquez. Farmacología Básica y Clínica (Editorial Médica Panamericana S.A.), pp. 957-972

2002

  1. Protocolo de detección y tratamiento de la tuberculosis latente

    Medicine: Programa de Formación Médica Continuada Acreditado, Vol. 8, Núm. 67, pp. 3607-3610

1998

  1. Unidad de enfermedades infecciosas del Hospital "12 de Octubre"(1989-1998)

    Tiempos médicos: revista de educación médica continuada, Núm. 554, pp. 79-81